The androgen receptor coactivator-binding interface

Androgen Action in Prostate Cancer

Volumn , Issue , 2009, Pages 297-311

  Estébanez Perpiñá, Eva ^b   Fletterick, Robert J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881260717     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69179-4_13     Document Type: Chapter

References (59)

1. Agoulnik I, Vaid A, Bingman WEIII, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL: Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res. 2005, 65:7976-7983.
2. Aranda A, Pascual A: Nuclear hormone receptors and gene expression. Physiol Rev 2001, 81:1269-1304.
3. Arnold LA, Estebanez-Perpina E, Togashi M, Jouravel N, Shelat A, McReynolds AC, Mar E, Nguyen P, Baxter JD, Fletterick RJ, Webb P, Guy RK: Discovery of small molecule inhibitors of the interaction of thyroid hormone receptor with transcriptional coregulators. J Biol Chem 2005, 280(52):43048-43055.
4. Arnold LA, Estebanez-Perpina E, Togashi M, Shelat A, Ocasio CA, McReynolds AC, Nguyen P, Baxter JD, Fletterick RJ, Webb P, Guy RK: A high-throughput screening method to identify small molecule inhibitors of thyroid hormone receptor coactivator binding. Sci STKE 2006, 341:13.
5. Arnold L, Kosinski A, Estébanez-Perpi-a E, Robert J, Fletterick Guy RK: Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem 2007, 50:5269-5280.
6. Askew E, Gampe RT Jr, Stanley TB, Faggart JL, Wilson EM: Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 2007, 282:25801-25816.
7. Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG: The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 1999, 19:8383-8392.
8. Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT: Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem 2005a, 280:37747-37754.
9. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT: Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 2005b, 102:6201-6206.
10. Bourguet W, Germain P, Gronemeyer H: Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 2000, 21:381-388.
11. Brelivet Y, Kammerer S, Rochel N, Poch O, Moras D: Signature of the oligomeric behaviour of nuclear receptors at the sequence and structural level. EMBO Rep 2004, 5:423-429.
12. Buchanan G, Yang M, Harris JM, Nahm HS, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR, et al: Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol 2001a, 15:46-56.
13. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD: Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001b, 7:1273-1281.
14. Burd CJ, Morey LM, Knudsen KE: Androgen receptor corepressors and prostate cancer. Endocr Relat Cancer 2006, 13:979-994.
15. Chang C, McDonnell DP: Androgen-receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol Sci 2005, 26:225-228.
16. Chang CY, Abdo J, Hartney T, McDonnell DP: Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Mol Endocrinol 2005, 19:2478-2490.
17. Chmelar R, Buchanan G, Need EF, Tilley W, Greenberg NM: Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 2007, 120:719-733.
18. Choudhry M, Ball A, McEwan IJ: The role of the general transcription factor IIF in androgen receptor-dependent transcription. Mol Endocrinol 2006, 20:2052-2061.
19. Darimont BD: Finding specificity within a conserved interaction site. Chem Biol 2003, 10:675-676.
20. Estébanez-Perpiñá EJN, Fletterick RJ: Perspectives on designs of antiandrogens for prostate cancer. Expert Opin Drug Discov 2007, 2:1341.
21. Estébanez-Perpiñá E, Moore JM, Mar E, Delgado-Rodrigues E, Nguyen P, Baxter JD, Buehrer BM, Webb P, Fletterick RJ, Guy RK: The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J Biol Chem 2005, 280:8060-8068.
22. Estébanez-Perpiñá E, Arnold AA, Nguyen P, Rodrigues ED, Mar E, Bateman R, Pallai P, Shokat KM, Baxter JD, Guy RK, Webb P, Fletterick RJ: A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci USA 2007a, 104:16074-16079.
23. Estébanez-Perpiñá E, Arnold LA, Jouravel N, Togashi M, Blethrow J, Mar E, Nguyen P, Phillips KJ, Baxter JD, Webb P, Guy RK, Fletterick RJ: Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor. Mol Endocrinol. 2007b, 21:2919-2928.
24. Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ, West BL: Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 1998, 280:1747-1749.
25. He B, Wilson EM: The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. Mol Genet Metab 2002, 75:293-298.
26. He B, Bowen NT, Minges JT, Wilson EM: Androgen-induced NH2-and COOH-terminal interaction inhibits p160 coactivator recruitment by activation function 2. J Biol Chem 2001, 276:42293-42301.
27. He B, Lee LW, Minges JT, Wilson EM: Dependence of selective gene activation on the androgen receptor NH2-and COOH-terminal interaction. J Biol Chem 2002, 277:25631-25639.
28. He B, Gampe RT Jr, Kole AJ, Hnat AT, Stanley TB, An G, Stewart EL, Kalman RI, Minges JT, Wilson EM: Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 2004, 16:425-438.
29. He B, Gampe RT Jr, Hnat AT, Faggart JL, Minges JT, French FS, Wilson EM: Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity. J Biol Chem 2006, 281:6648-6663.
30. Hodgson M, Astapova I, Cheng S, Lee LJ, Verhoeven MC, Choi E, Balk SP, Hollenberg AN: The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepris-tone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 2005, 280:6511-6519.
31. Hsu CL, Yeh S, Chen YL, Ting HJ, Hu YC, Lin H, Wang X, Chang C: The use of phage display technique for the isolation of androgen receptor interacting peptides with F/WXXLF/W and FXXLY new signature motifs. J Biol Chem 2003, 278:23691-23698.
32. Hsu CL, Chen YL, Ting HJ, Lin WJ, Yang Z, Zhang Y, Wang L, Wu CT, Chang HC, Yeh S, Pimplikar SW, Chang C: Androgen receptor (AR) NH2-and COOH-terminal interactions result in the differential influences on the AR-mediated transactivation and cell growth. Mol Endocrinol 2005, 19:350-361.
33. Hur E, Pfaff SJ, Sturgis PE, Hanne G, Buehrer BM, Fletterick RJ: Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS 2004, 2:363.
34. Jouravel N, Sablin E, Arnold LA, Guy RK, Fletterick RJ: Interaction between the androgen receptor and a segment of its corepressor SHP. Acta Crystallogr D Biol Crystallogr 2007, 63:1198-1200.
35. Lazar M: Nuclear receptor corepressors. Nucl Recept Signal. 2003, 1:e001.
36. Li J, Fu J, Toumazou C, Yoon HG, Wong J: A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. Mol Endocrinol 2006, 20:776-785.
37. Lonard DM, O'Malley BW: The expanding cosmos of nuclear receptor coactivators. Cell 2006, 125:411-414.
38. Lonard DM, O'Malley BW: Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 2007, 27:691-700.
39. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, et al: Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 2000, 275:26164-26171.
40. Matias PM, Carrondo MA, Coelho R, Thomaz M, Zhao XY, Wegg A, Crusius K, Egner U, Donner P: Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR (ccr)) derived from an androgen-independent prostate cancer. J Med Chem 2002, 45:1439-1446.
41. McKenna NJ, O'Malley BW: Minireview: nuclear receptor coactivators-an update. Endocrinology 2002, 143:2461-2465.
42. McKenna N, Xu J, Nawaz Z, Tsai SY, Tsai MJ, O'Malley BW: Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol 1999, 69:3-12.
43. McPhaul MJ: Androgen receptor mutations and androgen insensitivity. Mol Cell Endocrinol 2002, 198:61-67.
44. Milhon J, Lee S, Kohli K, Chen D, Hong H, Stallcup MR: Identification of amino acids in the tau 2-region of the mouse glucocorticoid receptor that contribute to hormone binding and tran-scriptional activation. Mol Endocrinol 1997, 11:1795-1805.
45. Moras D, Gronemeyer H: The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol 1998, 10:384-391.
46. Nichols M, Rientjes JM, Stewart AF: Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists. EMBO J 1998, 17:765-773.
47. Pereira de J, Jesus-Tran K, Cote PL, Cantin L, Blanchet J, Labrie F, Breton R: Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci 2006, 15:987-999.
48. Prescott J, Coetzee GA: Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett 2006, 231:12-19.
49. Quigley C, Tan JA, He B, Zhou ZX, Mebarki F, Morel Y, Forest MG, Chatelain P, Ritzén EM, French FS, Wilson EM: Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)-and carboxyl-terminal interaction. Mech Ageing Dev 2004, 125:683-689.
50. Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, Wu GY, Scheffler JE, Salvati ME, Krystek SR, Jr., et al: Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestoster-one. Proc Natl Acad Sci USA 2001, 98:4904-4909.
51. Salvati M, Balog A, Shan W, Wei DD, Pickering D, Attar RM, Geng J, Rizzo CA, Gottardis MM, Weinmann R, Krystek SR, Sack J, An Y, Kish K: Structure based approach to the design of bicyclic-1H-isoindole-1, 3(2H)-dione based androgen receptor antagonists. Bioorg Med Chem Lett 2005, 15:271-276.
52. Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT: Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci USA 2004, 101:4758-4763.
53. Shang Y, Myers M, Brown M: Formation of the androgen receptor transcription complex. Mol Cell 2002, 9:601-610.
54. Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW: Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002, 62:1496-1502.
55. Tanenbaum DM, Wang Y, Williams SP, Sigler PB: Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci USA 1998, 95:5998-6003.
56. Wang L, Hsu CL, Chang C: Androgen receptor corepressors: an overview. Prostate 2005, 63:117-130.
57. Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, Gronemeyer H: A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 1996, 3:206.
58. Yeh S, Chang C: Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 1996, 93:5517-5521.
59. Zhou ZX, He B, Hall SH, Wilson EM, French FS: Domain interactions between coregulator ARA (70) and the androgen receptor (AR). Mol Endocrinol 2002, 16:287-300.